Photo by diana_pole from unsplash
asthma and eczema, and plays a role in controlling the trafficking of immune cells. The surface receptor has stymied the efforts of small-molecule drug developers, but scientists at Kyowa Hakko… Click to show full abstract
asthma and eczema, and plays a role in controlling the trafficking of immune cells. The surface receptor has stymied the efforts of small-molecule drug developers, but scientists at Kyowa Hakko Kirin found that their mogamulizumab binds to CCR4 on cancer cells, killing them via antibody-dependent cellular cytotoxicity. The FDA approved the antibody for the treatment of two subtypes of cutaneous T cell lymphoma. In a pivotal trial of 372 patients with these subtypes, patients assigned to mogamulizumab had a median progression-free survival of 7.6 months, compared with 3.1 months for patients assigned to the histone deacetylase inhibitor vorinostat. (Japanese FDA approves second GPCR-targeted antibody
Journal Title: Nature Reviews Drug Discovery
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!